Vivos Inc (RDGL)

[bdvest]

Richland WA, March 04, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTCPINK: RDGL), provides a summary of the previous update on dogs that have been treated to date in the canine soft tissue sarcoma series.

Dr. Mike Korenko, Vivos Inc CEO stated “On February 25, 2019 we provided a detailed update on the status of dogs that have been treated to date with Y-90 IsoPet at the University of Missouri Center for Veterinary Medicine. Reporting results on therapies at the University of Missouri requires their review and approval. As a result, the last press release was technically accurate, but included terminology commonly used by veterinary professionals but not generally understood by the general public. For that reason, I believe that it is necessary to provide the following summary observations:

IsoPet® is easily administered in an outpatient setting using the procedures provided in the product labeling.

IsoPet® killed any cancer cells that came within the treatment zone.
Biologically it takes time for the dead tissue to resorb, but the rate and quality of normal tissue regeneration is encouraging.

I am confident that IsoPet extended the duration and quality of life of the patients that were treated.

I was particularly impressed that IsoPet effectively stopped the growth of a half-pound tumor.

IsoPet® is a great product and we are looking forward to making it available commercially.”